Linezolid-induced hypoglycaemia in a patient with type 1 diabetes-Reference-Cited by-同舟云学术

Linezolid-induced hypoglycaemia in a patient with type 1 diabetes

Published:2012-07 Issue:4 Volume:12 Page:186-188
ISSN:1474-6514
Container-title:The British Journal of Diabetes & Vascular Disease
language:en
Short-container-title:Diabetes & Vascular Disease

Author:

Walker Kerry¹,Toshner Richard¹,Sandeep Thekkepat C¹,Devers Marion¹,Bain Donald²,Barwell Nicholas³

Affiliation:

1. David Matthews Diabetes Centre, Monklands Hospital, Airdrie, Scotland, UK

2. Department of Vascular Surgery, Hairmyres Hospital, East Kilbride, Scotland, UK

3. Department of Diabetes, Forth Valley Royal Hospital, Larbert, Scotland, UK

Abstract

Linezolid is a relatively novel oxazolidinone and its use is currently limited to secondary care in the UK. It is a reversible, non-selective monoamine oxidase inhibitor, but at the doses used for antibacterial therapy it does not exert an anti-depressive effect. It has a potentially serious side effect profile and is monitored intensively by the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency. Herein we report the rarely recognised complication of linezolid-induced hypoglycaemia in a patient with type 1 diabetes.

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1474651412458530

Reference11 articles.

1. The global burden of diabetic foot disease

2. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study

3. Diagnosis and Treatment of Diabetic Foot Infections

4. Linezolid: a review of safety and tolerability

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic foot infection: Antibiotic therapy and good practice recommendations;International Journal of Clinical Practice;2017-09-11

2. Linezolid;Reactions Weekly;2012-12